Eli Lilly and (LLY) Financials: History & Chart

Eli Lilly and Company (LLY)LLYEli Lilly and Company

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Indianapolis, IN

50,000 employees

www.lilly.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: David A. Ricks

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	72.25B	19.80B	19.29B	17.60B	15.56B	12.73B	13.53B	11.44B	11.30B
Cost of Goods Sold	11.92B	3.58B	2.88B	3.01B	2.45B	2.22B	2.40B	2.17B	2.17B
Gross Profit	60.33B	16.22B	16.41B	14.59B	13.11B	10.50B	11.13B	9.27B	9.13B
Gross Profit Margin	83.5%	81.9%	85.1%	82.9%	84.3%	82.5%	82.2%	81.0%	80.8%
Total Operating Expenses	27.20B	7.37B	7.63B	6.21B	5.98B	5.10B	5.33B	4.72B	4.71B
Research & Development	14.11B	3.51B	3.80B	3.47B	3.34B	2.73B	3.02B	2.73B	2.71B
Selling, General & Administrative	11.67B	2.93B	3.34B	2.74B	2.65B	2.36B	2.31B	1.98B	2.00B
Operating Income (EBIT)	33.14B	8.85B	8.78B	8.39B	7.13B	5.41B	5.80B	4.55B	4.42B
Operating Margin	45.9%	44.7%	45.5%	47.6%	45.8%	42.5%	42.8%	39.8%	39.1%
Income Before Tax (EBT)	31.12B	8.85B	8.27B	7.23B	6.78B	3.46B	5.04B	1.59B	3.52B
Interest Income	105.00M	N/A	N/A	65.00M	40.00M	48.30M	44.30M	47.80M	37.30M
Interest Expense	883.60M	332.00M	123.00M	179.60M	249.00M	243.70M	224.70M	192.70M	183.60M
Other Income/Expense	-2.01B	0.00	-509.20M	-1.15B	-349.80M	-1.95B	-759.10M	-2.96B	-901.30M
Net Income	25.27B	7.40B	6.64B	5.58B	5.66B	2.76B	4.41B	970.30M	2.97B
Income Tax Expense	5.85B	1.45B	1.63B	1.65B	1.12B	696.80M	628.90M	618.10M	550.20M
Net Profit Margin	35.0%	37.4%	34.4%	31.7%	36.4%	21.7%	32.6%	8.5%	26.3%
EBITDA	34.75B	9.36B	8.93B	8.86B	7.60B	5.87B	6.28B	5.02B	4.83B
EBITDA Margin	48.1%	47.3%	46.3%	50.3%	48.9%	46.1%	46.4%	43.9%	42.8%
Depreciation & Amortization	1.61B	509.00M	152.20M	470.00M	478.50M	462.80M	484.80M	466.80M	414.40M
EPS Basic	28.20	8.27	7.41	6.22	6.30	3.07	4.91	1.08	3.29
EPS Diluted	28.15	8.26	7.39	6.21	6.29	3.06	4.88	1.07	3.28
Shares Outstanding	894.50M	894.50M	898.00M	896.90M	897.90M	897.99M	897.54M	901.00M	900.90M
Diluted Shares Outstanding	895.90M	895.90M	898.00M	898.80M	899.79M	900.60M	903.16M	905.00M	904.20M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	65.18B	45.04B	34.12B	28.54B	28.32B	24.54B	22.32B	21.49B
Cost of Goods Sold	10.56B	8.42B	7.08B	6.63B	7.31B	5.48B	4.72B	4.68B
Gross Profit	54.62B	36.62B	27.04B	21.91B	21.01B	19.06B	17.60B	16.81B
Gross Profit Margin	83.8%	81.3%	79.2%	76.8%	74.2%	77.7%	78.8%	78.2%
Total Operating Expenses	24.92B	19.12B	16.25B	13.26B	13.07B	11.85B	11.60B	10.79B
Research & Development	13.34B	10.99B	9.31B	7.19B	6.93B	5.98B	5.59B	5.05B
Selling, General & Administrative	11.09B	8.13B	6.94B	6.07B	6.14B	5.87B	6.00B	5.73B
Operating Income (EBIT)	29.70B	17.50B	10.79B	8.65B	7.93B	7.21B	6.00B	6.03B
Operating Margin	45.6%	38.9%	31.6%	30.3%	28.0%	29.4%	26.9%	28.0%
Income Before Tax (EBT)	25.73B	12.68B	6.55B	6.81B	6.16B	7.23B	5.27B	3.68B
Interest Income	153.30M	175.20M	173.60M	62.80M	25.40M	33.00M	80.40M	159.30M
Interest Expense	795.30M	780.60M	485.90M	331.60M	339.80M	359.60M	400.60M	242.50M
Other Income/Expense	-3.96B	-4.82B	-4.23B	-1.85B	-1.78B	19.10M	-733.50M	-2.35B
Net Income	20.64B	10.59B	5.24B	6.24B	5.58B	6.19B	8.32B	3.23B
Income Tax Expense	5.09B	2.09B	1.31B	561.60M	573.80M	1.04B	628.00M	529.50M
Net Profit Margin	31.7%	23.5%	15.4%	21.9%	19.7%	25.2%	37.3%	15.0%
EBITDA	31.26B	19.27B	12.31B	10.18B	9.48B	8.53B	7.23B	7.63B
EBITDA Margin	48.0%	42.8%	36.1%	35.7%	33.5%	34.8%	32.4%	35.5%
Depreciation & Amortization	1.56B	1.77B	1.53B	1.52B	1.55B	1.32B	1.23B	1.61B
EPS Basic	23.00	11.76	5.83	6.57	5.85	6.47	8.69	3.14
EPS Diluted	22.95	11.71	5.80	6.57	5.85	6.47	8.69	3.13
Shares Outstanding	898.00M	900.61M	899.38M	950.18M	953.65M	956.59M	957.53M	1.03B
Diluted Shares Outstanding	898.00M	904.06M	903.28M	950.18M	953.65M	956.59M	957.53M	1.03B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.